News
Check here regularly for updates on activities within the Program and its projects.
Pacylex Pharmaceuticals Begins Phase I Clinical Trial (Sept. 14, 2021).
Local startup Pacylex Pharmaceuticals Inc. today initiated the PCLX-001-01 Phase I clinical trial at the Cross Cancer Institute in Edmonton. The focus of the trial will be the safety and tolerability of its lead anti-cancer drug, PCLX-001, and determination of an appropriate dose for future Phase II and III studies. In the trial, PCLX-001 will be tested in a limited number of patients with lymphoma or solid tumour malignancies.
Pacylex was formed around discoveries in the University of Alberta lab of Dr. Luc Berthiaume. The trial represents a successful translation of discovery research to human clinical testing, and highlights the role of the PP1P: to accelerate Alberta-based innovations to the clinic. This endeavour brings a novel new drug candidate to first-in-human testing. For more information, please refer to the links below.
PharmaMatrix Holdings Ltd Begins Phase I Clinical Trial (September 29, 2021).
Local startup PharmaMatrix Holdings Ltd. today initiated the PMH-001 Phase I clinical trial at the Cross Cancer Institute in Edmonton to test its lead anti-cancer drug, CCI-001. The focus of the trial will be the safety and tolerability of CCI-001, and determination of an appropriate dose for future Phase II and III studies. In the trial, CCI-001 will be tested in a limited number of patients with recurrent and/or metastatic solid tumours.
The CCI-001 drug candidate is the product of computational modelling by the University of Alberta lab of Dr. Jack Tuszynski. The trial is another example of successful translation of Alberta-based research, bringing a novel new drug candidate to first-in-human testing. For more information, please refer to the links below.
Print